{"id":"9fa781d4-8eb2-5704-8cf3-999caf38f93c","stable_key":"d96b230c-481b-535b-930c-04eb87ec7f02:s-allylcysteine-nitrate-combination","predicate":"reduces_reported","statement":"An uncontrolled 12-person nitrate/garlic combination study reported lower systolic pressure after two weeks, persisting at four weeks.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"9c107d9e-073a-58cd-ae79-2fba93579100","mechanism_event_label":"A cross-compound human lead remains available without assigning the effect to SAC.","subject":{"id":"98ecad89-e142-5200-a6c8-ec6f1b61ea98","slug":"vascanox-hp-2023","display_name":"Vascanox HP nitrate/garlic combination studied in 2023","entity_type_key":"chemical_species"},"object":{"id":"8cb6bbaa-08b8-5eb0-be9b-6dda99fdde79","slug":"human-vascanox-bp-readout","display_name":"Blood-pressure readout in the 2023 Vascanox open-label study","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"9c107d9e-073a-58cd-ae79-2fba93579100","stable_key":"d96b230c-481b-535b-930c-04eb87ec7f02:s-allylcysteine-nitrate-combination-event","event_type":"observed_relationship","label":"A cross-compound human lead remains available without assigning the effect to SAC.","description":"An uncontrolled 12-person nitrate/garlic combination study reported lower systolic pressure after two weeks, persisting at four weeks.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"98ecad89-e142-5200-a6c8-ec6f1b61ea98","slug":"vascanox-hp-2023","display_name":"Vascanox HP nitrate/garlic combination studied in 2023","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"8cb6bbaa-08b8-5eb0-be9b-6dda99fdde79","slug":"human-vascanox-bp-readout","display_name":"Blood-pressure readout in the 2023 Vascanox open-label study","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"8c2c295d-68b3-5e62-b1a7-00fcf915e3cc","slug":"s-allylcysteine","display_name":"S-allyl-L-cysteine / SAC","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"9ec2c9b8-c1c2-53e5-8e72-6a88638b814e","slug":"nitrate-ion","display_name":"Nitrate ion","entity_type_key":"ion"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"03ffed32-aa18-5d63-96a4-8a7ebedaf7a9","slug":"nitrite","display_name":"Nitrite / NO2(-)","entity_type_key":"ion"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"acting_entity","value_text":"vascanox-hp-2023","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"dose","value_text":"Vascanox HP combination; constituent doses not retrieved","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"Four weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_comparison","value_text":"Within-person baseline; no placebo or factorial comparison","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Twelve participants completing an open-label combination study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived research curation; not independent primary verification","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"No placebo or ingredient-factorial arms: cannot establish SAC contribution, nitrate contribution, interaction or synergy.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"S-allylcysteine collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"s-allylcysteine","display_name":"S-allyl-L-cysteine / SAC","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A cross-compound human lead remains available without assigning the effect to SAC.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[37849591] Effects of S-Allylcysteine-Rich Garlic Extract and Dietary Inorganic Nitrate Formula on Blood Pressure and Salivary Nitric Oxide: An Open-Label Clinical Trial Among Hypertensive Subjects. · 2023 · https://pubmed.ncbi.nlm.nih.gov/37849591/ · DOI 10.7759/cureus.45369","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Twelve participants completing an open-label combination study","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"0cbe8a16-562b-556e-be10-61194d9fcd79","evidence_kind":"source_excerpt","locator":"Lines 455-462","start_line":455,"end_line":462,"excerpt":"## s-allylcysteine-nitrate-combination\nA cross-compound human lead remains available without assigning the effect to SAC.\nAn uncontrolled 12-person nitrate/garlic combination study reported lower systolic pressure after two weeks, persisting at four weeks.\nModel: Twelve participants completing an open-label combination study\nLimitations: No placebo or ingredient-factorial arms: cannot establish SAC contribution, nitrate contribution, interaction or synergy.\nEvidence access: Primary abstract\n[37849591] Effects of S-Allylcysteine-Rich Garlic Extract and Dietary Inorganic Nitrate Formula on Blood Pressure and Salivary Nitric Oxide: An Open-Label Clinical Trial Among Hypertensive Subjects. · 2023 · https://pubmed.ncbi.nlm.nih.gov/37849591/ · DOI 10.7759/cureus.45369\nStructured context: {\"organism\": \"Homo sapiens\", \"tissue_or_cell_type\": \"Twelve participants completing an open-label combination study\", \"dose\": \"Vascanox HP combination; constituent doses not retrieved\", \"duration\": \"Four weeks\", \"route\": \"Oral\", \"experimental_comparison\": \"Within-person baseline; no placebo or factorial comparison\", \"acting_entity\": \"vascanox-hp-2023\", \"interpretation_status\": \"Source-derived research curation; not independent primary verification\"}","model_system":"Twelve participants completing an open-label combination study","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"3b0d58f9-8a69-579d-9920-518399a9a8bb","stable_key":"import-d96b230c-481b-535b-930c-04eb87ec7f02","title":"S-allylcysteine: sulfur signaling, redox responses and cross-nutrient mechanisms (2026-09-20)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"91d7aeac82e42ce559d13dd8a2e0165d37760f7f555dd01c80e0604fa6e71ea2","revision_id":"545e497c-e5e3-543c-b26b-b297cbc7bbec","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}